account adjust acquisition-rel cost certain
signific item
modest beat top bottom line revenu guidanc narrow ep
ep estim consensu ep
guidanc increas prior includ fx
impact vs prior fx impact last publish ep estim
sale estim
consensu product beat forecast includ keytruda isentress
januvia simponi gardasil remicad singulair vytorin
combin estim product forecast includ zetia
zepati cubicin zostavax combin
forecast anim health sale estim revenu
guidanc narrow includ slight posit fx impact prior
fx impact last publish revenu estim
gpm estim
estim sg flat forecast net non-
op incom estim tax rate
forecast ad ep share count
estim guidanc updat gpm approxim vs
prior slightli lower tax rate vs prior
keytruda /eu approv nsclc w/alimta chemo pdufa
 approv pdufa squamou nsclc w/chemo
pdufa regular approv pdufa
acceler approv data neoadjuvant/adjuv tnbc januvia next
step post apr label inclus teco data doravirin approv
hiv mono tablet fdc lamivudin tenofovir pdufa lynparza
w/azn full data regulatori file brcam ovarian cancer lenvima w/
data vabp relebactem w/imipenem cilastin file imipenem non-suscept
infect gardasil label updat expand use age yo pdufa
pleas see page report import disclosur
merck competit posit line lung cancer clear posit merck face
uncertainti includ januvia outlook competit market remicad zetia
vytorin cubicin nasonex biosimilars/gener competit pressur isentress
zostavax believ risk balanc opportun therefor remain market
perform stock
uptak keytruda nsclc
keytruda data readout variou tumor
keytruda approv
nsclc w/chemo
lynparza full data/fil ovarian
oper margin improv
keytruda data and/or uptak lung
posit expect
new product unabl off-set nasonex
vytorin/zetia cubicin patent
expir competit pressur
zostavax isentress
merck global health care compani includ prescript medicin vaccin
biolog therapi anim health strong product presenc oncolog
cardiovascular anti-infect anti-inflammatori diabet area among other
anim health divis focus mainli feed anim
cowen compani
cowen compani compani data
cowen compani
cowen compani
cowen compani
m-m-r ii cowen
valuat methodolog primarili base current year forward price-to-earnings multipl
also consid total return/p ratio market cap/fre cash flow metric
failur pipelin product intellectu properti challeng econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend fluctuat foreign exchang rate
risk includ continu success exist portfolio notabl januvia vytorin
zetia isentress success pipelin product especi suvorex odanacatib
anacetrapib lambrolizumab success deal patent litig patent
expir pressur binari risk includ safeti issu involv odanacatib
improve-it studi vytorin
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
cowen compani llc affili make market stock merck secur
author report member author household long posit equiti secur merck
author report member author household long posit equiti secur
cowen compani llc compens research analyst activ servic intend benefit firm investor client individu compens determin research
analyst includ author report base varieti factor includ overal profit firm total revenu deriv sourc includ
revenu invest bank sale trade princip trade revenu cowen compani llc compens research analyst base specif invest
bank transact specif sale trade princip trade revenu
research report simultan avail client client websit research report client research report dissemin e-mail
made avail third-parti aggreg cowen compani llc respons redistribut research third parti aggreg select research report
avail print form addit electron form publish research report obtain firm client websit http //cowenlibrari bluematrix com/client/
inform opinion estim forecast date report subject chang without prior notif seek updat research appropri
variou regul may prevent us research report publish irregular interv appropri analyst judgement
inform subject secur may obtain offic research report publish sole inform purpos constru offer
sell solicit offer buy secur state offer solicit would illeg disclosur relat cowen compani llc
